ReviewClinical and experimental nephrology2014
Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.
Review in Clinical and experimental nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes.PloS one · 2018Trial
- Targeting p66Shc to restore KFrontiers in physiology · 2025Article
- Article
- Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes.Diabetes care · 2022Article
- Pathologic Diabetic Nephropathy in Autopsied Diabetic Cases With Normoalbuminuria From a Japanese Community-Based Study.Kidney international reports · 2021Article
- Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (Journal of the American Society of Nephrology : JASN · 2021Article
- Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus.Diabetologia · 2020Article
- Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus.Physiological reports · 2019Article
- Risk Factors for Kidney Disease in Type 1 Diabetes.Diabetes care · 2019Article
- Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus.Diabetologia · 2017Article
- Resting Heart Rate Does Not Predict Cardiovascular and Renal Outcomes in Type 2 Diabetic Patients.Journal of diabetes research · 2016Article
- Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.Diabetes · 2015Article
- Diabetic kidney disease.Nature reviews. Disease primers · 2015Review
- Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes.Diabetes care · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Despite almost universal implementation of renoprotective therapies over the past 25 years, the risk of end-stage renal disease (ESRD) in type 1 diabetes (T1D) is not decreasing, and ESRD remains the major cause of excess morbidity and premature mortality [1]. Such a state of affairs prompts a call to action. In this review we re-evaluated the proteinuria-centric model of diabetic nephropathy and showed its deficiencies. On the basis of extensive studies that we have been conducting on the patients attending the Joslin Clinic, we propose that progressive renal decline, not abnormalities in urinary albumin excretion, should be considered as the major feature of disease processes leading to ESRD in T1D. The etiology of diabetic nephropathy should be reconsidered in light of our new findings so our perspective can be broadened regarding new therapeutic targets available for interrupting the progressive renal decline in T1D. Reduction in the loss of glomerular filtration rate, not reduction of albumin excretion rate, should become the measure for evaluating the effectiveness of new therapeutic interventions. We need new accurate methods for early diagnosis of patients at risk of progressive renal decline or, better still, for detecting in advance which patients will have rapid, moderate or minimal rate of progression to ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.